The best and worst of times in therapy development for myasthenia gravis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36321730/
Within the last 5 years the U.S. Federal Drug Administration (FDA) has approved complement and neonatal Fc receptor (FcRN)-inhibitors for treatment of generalized myasthenia gravis; and several other therapies are in late stage clinical trials or under regulatory review. Questions, however, about wh ...
Relevance: The authors provide a summary of these discussions, but not a consensus opinion, and offer a series of recommendations to guide focused research in the most critical areas. We welcome ongoing discussion through comments on this publication.